JP2016505039A5 - - Google Patents

Download PDF

Info

Publication number
JP2016505039A5
JP2016505039A5 JP2015553775A JP2015553775A JP2016505039A5 JP 2016505039 A5 JP2016505039 A5 JP 2016505039A5 JP 2015553775 A JP2015553775 A JP 2015553775A JP 2015553775 A JP2015553775 A JP 2015553775A JP 2016505039 A5 JP2016505039 A5 JP 2016505039A5
Authority
JP
Japan
Prior art keywords
phenyl
metformin
glp1r agonist
glp1r
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015553775A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016505039A (ja
JP6445459B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/011394 external-priority patent/WO2014113357A1/en
Publication of JP2016505039A publication Critical patent/JP2016505039A/ja
Publication of JP2016505039A5 publication Critical patent/JP2016505039A5/ja
Application granted granted Critical
Publication of JP6445459B2 publication Critical patent/JP6445459B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015553775A 2013-01-17 2014-01-14 Glp1rアゴニストとメトホルミンの組合わせおよび2型糖尿病その他の障害の処置のためのその使用 Active JP6445459B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361753567P 2013-01-17 2013-01-17
US61/753,567 2013-01-17
PCT/US2014/011394 WO2014113357A1 (en) 2013-01-17 2014-01-14 Combinations of a glp1r agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders

Publications (3)

Publication Number Publication Date
JP2016505039A JP2016505039A (ja) 2016-02-18
JP2016505039A5 true JP2016505039A5 (enExample) 2017-02-16
JP6445459B2 JP6445459B2 (ja) 2018-12-26

Family

ID=50030537

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015553775A Active JP6445459B2 (ja) 2013-01-17 2014-01-14 Glp1rアゴニストとメトホルミンの組合わせおよび2型糖尿病その他の障害の処置のためのその使用

Country Status (13)

Country Link
US (1) US20150313908A1 (enExample)
EP (1) EP2945618B1 (enExample)
JP (1) JP6445459B2 (enExample)
KR (1) KR102165434B1 (enExample)
CN (1) CN104968341B (enExample)
AU (1) AU2014207748B2 (enExample)
CA (1) CA2896308C (enExample)
EA (1) EA201591123A1 (enExample)
ES (1) ES2687083T3 (enExample)
IL (1) IL239714A0 (enExample)
MX (1) MX366685B (enExample)
SG (2) SG10201704716XA (enExample)
WO (1) WO2014113357A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019060653A1 (en) 2017-09-22 2019-03-28 Regeneron Pharmaceuticals, Inc. GLP-1 RECEPTOR AGONISTS (GLUCAGON-LIKE PEPTIDE 1) AND USES THEREOF
CA3090823A1 (en) * 2018-05-08 2019-11-14 Vtv Therapeutics Llc Therapeutic uses of glp1r agonists
CN115461344B (zh) * 2020-04-01 2024-01-12 杭州中美华东制药有限公司 一种glp-1受体激动剂的晶型a及其制备方法
WO2021196951A1 (zh) * 2020-04-01 2021-10-07 杭州中美华东制药有限公司 Glp-1受体激动剂游离碱的药学上可接受的酸式盐及其制备方法
EP4272733A4 (en) * 2020-12-31 2024-07-10 Dong Kook Pharm. Co., Ltd PHARMACEUTICAL COMPOSITION CONTAINING TADALAFIL OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND DUTASTERIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF HAVING A NOVEL DISSOLUTION RATE
WO2024064842A1 (en) 2022-09-21 2024-03-28 Regeneron Pharmaceuticals, Inc. Methods of treating obesity, diabetes, and liver dysfunction
WO2025158275A1 (en) 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080472A (en) 1974-03-22 1978-03-21 Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S. Metformin 2-(p-chlorophenoxy)-2-methylpropionate
JP2009514896A (ja) * 2005-11-07 2009-04-09 エリクシアー ファーマシューティカルズ, インコーポレイテッド メトホルミンおよびメグリチニドの組み合わせ
WO2009111700A2 (en) * 2008-03-07 2009-09-11 Transtech Pharma, Inc. Oxadiazoanthracene compounds for the treatment of diabetes
CN102378574B (zh) 2009-03-30 2013-11-20 转化技术制药公司 取代的偶氮蒽衍生物、药物组合物及其使用方法
WO2011031620A1 (en) 2009-09-11 2011-03-17 Transtech Pharma, Inc. Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same
CA2780460C (en) * 2009-11-13 2018-09-04 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
US20110118180A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to metformin
US20130040878A1 (en) * 2011-05-13 2013-02-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in the treatment of diabetes type 2 patients

Similar Documents

Publication Publication Date Title
JP2016505039A5 (enExample)
AU2012330885B2 (en) Oral immediate release formulations for substituted quinazolinones
TWI329014B (en) Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or h3receptor antagonist/inverse agonist
JP2014528474A5 (enExample)
JP2015523397A5 (enExample)
JP2009542702A5 (enExample)
JP2009542699A5 (enExample)
JP2017528507A5 (enExample)
JP2023024704A (ja) 絶食条件下でのタシメルテオンの投与
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
JP2016510326A5 (enExample)
JP6445459B2 (ja) Glp1rアゴニストとメトホルミンの組合わせおよび2型糖尿病その他の障害の処置のためのその使用
JP2020529440A5 (enExample)
JP2012502103A5 (enExample)
EP4233913A3 (en) Improved bromocriptine formulations
WO2018005794A3 (en) Novel non-systemic tgr5 agonists
CN104667283B (zh) 一种治疗血脂异常和动脉粥样硬化的复方药物组合
JP2014511365A5 (enExample)
JP2017509628A5 (enExample)
CN101610760A (zh) 恶病质的治疗
JP2019528290A5 (enExample)
JP2009506043A5 (enExample)
CN104114165B (zh) 用于治疗憩室病的方法和组合物
TW200922546A (en) Galenical formulations of organic compounds
JP2020536068A5 (enExample)